

Werner B F Brouwer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2622704/publications.pdf>

Version: 2024-02-01

182
papers

7,851
citations

50170

46
h-index

64668

79
g-index

186
all docs

186
docs citations

186
times ranked

7980
citing authors

#	ARTICLE	IF	CITATIONS
1	Once we have it, will we use it? A European survey on willingness to be vaccinated against COVID-19. <i>European Journal of Health Economics</i> , 2020, 21, 977-982.	1.4	760
2	The CarerQol instrument: A new instrument to measure care-related quality of life of informal caregivers for use in economic evaluations. <i>Quality of Life Research</i> , 2006, 15, 1005-1021.	1.5	298
3	The iMTA Productivity Cost Questionnaire. <i>Value in Health</i> , 2015, 18, 753-758.	0.1	298
4	Welfarism vs. extra-welfarism. <i>Journal of Health Economics</i> , 2008, 27, 325-338.	1.3	260
5	Discounting in Economic Evaluations. <i>Pharmacoeconomics</i> , 2018, 36, 745-758.	1.7	210
6	Productivity losses without absence: measurement validation and empirical evidence. <i>Health Policy</i> , 1999, 48, 13-27.	1.4	199
7	Need for differential discounting of costs and health effects in cost effectiveness analyses. <i>BMJ: British Medical Journal</i> , 2005, 331, 446-448.	2.4	171
8	Process utility from providing informal care: the benefit of caring. <i>Health Policy</i> , 2005, 74, 85-99.	1.4	158
9	Discounting and decision making in the economic evaluation of health-care technologies. <i>Health Economics (United Kingdom)</i> , 2011, 20, 2-15.	0.8	156
10	Caring for and caring about: Disentangling the caregiver effect and the family effect. <i>Journal of Health Economics</i> , 2010, 29, 549-556.	1.3	153
11	United but divided: Policy responses and people's perceptions in the EU during the COVID-19 outbreak. <i>Health Policy</i> , 2020, 124, 909-918.	1.4	147
12	Quality of life instruments for economic evaluations in health and social care for older people: A systematic review. <i>Social Science and Medicine</i> , 2014, 102, 83-93.	1.8	146
13	How to Estimate Productivity Costs in Economic Evaluations. <i>Pharmacoeconomics</i> , 2014, 32, 335-344.	1.7	144
14	Productivity Costs Measurement Through Quality of Life? A Response to the Recommendation of the Washington Panel. , 1997, 6, 253-259.		136
15	How to Include Informal Care in Economic Evaluations. <i>Pharmacoeconomics</i> , 2013, 31, 1105-1119.	1.7	115
16	Patient and general public preferences for health states: A call to reconsider current guidelines. <i>Social Science and Medicine</i> , 2016, 165, 66-74.	1.8	110
17	Public views on principles for health care priority setting: Findings of a European cross-country study using Q methodology. <i>Social Science and Medicine</i> , 2015, 126, 128-137.	1.8	108
18	Discounting in economic evaluations: stepping forward towards optimal decision rules. <i>Health Economics (United Kingdom)</i> , 2007, 16, 307-317.	0.8	103

#	ARTICLE	IF	CITATIONS
19	Do Productivity Costs Matter?. <i>Pharmacoeconomics</i> , 2011, 29, 601-619.	1.7	102
20	How to govern the digital transformation of health services. <i>European Journal of Public Health</i> , 2019, 29, 7-12.	0.1	98
21	Reconciliation of Economic Concerns and Health Policy. <i>Pharmacoeconomics</i> , 2004, 22, 1097-1107.	1.7	95
22	Willingness to Pay for a Quality-Adjusted Life-Year: The Individual Perspective. <i>Value in Health</i> , 2010, 13, 1046-1055.	0.1	88
23	Subjective caregiver burden of parents of adults with Duchenne muscular dystrophy. <i>Disability and Rehabilitation</i> , 2012, 34, 988-996.	0.9	85
24	A Framework for Including Family Health Spillovers in Economic Evaluation. <i>Medical Decision Making</i> , 2016, 36, 176-186.	1.2	82
25	Balancing equity and efficiency in the Dutch basic benefits package using the principle of proportional shortfall. <i>European Journal of Health Economics</i> , 2013, 14, 107-115.	1.4	80
26	Health Effects in Significant Others. <i>Medical Decision Making</i> , 2011, 31, 292-298.	1.2	77
27	A new test of the construct validity of the CarerQol instrument: measuring the impact of informal care giving. <i>Quality of Life Research</i> , 2011, 20, 875-887.	1.5	75
28	Measuring the impact of caregiving on informal carers: a construct validation study of the CarerQol instrument. <i>Health and Quality of Life Outcomes</i> , 2013, 11, 173.	1.0	74
29	From Good to Better: New Dutch Guidelines for Economic Evaluations in Healthcare. <i>Pharmacoeconomics</i> , 2016, 34, 1071-1074.	1.7	74
30	Productivity costs before and after absence from work: as important as common?. <i>Health Policy</i> , 2002, 61, 173-187.	1.4	73
31	When is it too expensive? Cost-effectiveness thresholds and health care decision-making. <i>European Journal of Health Economics</i> , 2019, 20, 175-180.	1.4	73
32	Give me a break!. <i>Health Policy</i> , 2008, 88, 73-87.	1.4	71
33	Unrelated Medical Costs in Life-Years Gained. <i>Pharmacoeconomics</i> , 2008, 26, 815-830.	1.7	68
34	Measuring Health Spillovers for Economic Evaluation: A Case Study in Meningitis. <i>Health Economics (United Kingdom)</i> , 2016, 25, 1529-1544.	0.8	68
35	A Dollar Is a Dollar Is a Dollar or Is It?. <i>Value in Health</i> , 2006, 9, 341-347.	0.1	63
36	A Discrete Choice Experiment to Obtain a Tariff for Valuing Informal Care Situations Measured with the CarerQol Instrument. <i>Medical Decision Making</i> , 2014, 34, 84-96.	1.2	63

#	ARTICLE	IF	CITATIONS
37	Capabilities and quality of life in Dutch psycho-geriatric nursing homes: an exploratory study using a proxy version of the ICECAP-O. <i>Quality of Life Research</i> , 2012, 21, 801-812.	1.5	59
38	Acceptability of less than perfect health states. <i>Social Science and Medicine</i> , 2005, 60, 237-246.	1.8	56
39	Treatment for Sleep Problems in Children with Autism and Caregiver Spillover Effects. <i>Journal of Autism and Developmental Disorders</i> , 2015, 45, 3613-3623.	1.7	56
40	Looking back and moving forward: On the application of proportional shortfall in healthcare priority setting in the Netherlands. <i>Health Policy</i> , 2018, 122, 621-629.	1.4	55
41	The Relationship between Productivity and Health-Related QOL. <i>Pharmacoeconomics</i> , 2005, 23, 209-218.	1.7	54
42	Sustained informal care: The feasibility, construct validity and test-retest reliability of the CarerQol-instrument to measure the impact of informal care in long-term care. <i>Aging and Mental Health</i> , 2011, 15, 1018-1027.	1.5	54
43	The influence of subjective life expectancy on health state valuations using a 10 year TTO. <i>Health Economics (United Kingdom)</i> , 2009, 18, 549-558.	0.8	51
44	Should I stay or should I go? Waiting lists and cross-border care in the Netherlands. <i>Health Policy</i> , 2003, 63, 289-298.	1.4	50
45	Expectations regarding length and health related quality of life: Some empirical findings. <i>Social Science and Medicine</i> , 2005, 61, 1083-1094.	1.8	50
46	Too Important to Ignore. <i>Pharmacoeconomics</i> , 2006, 24, 39-41.	1.7	50
47	The Value of a QALY: Individual Willingness to Pay for Health Gains Under Risk. <i>Pharmacoeconomics</i> , 2014, 32, 75-86.	1.7	50
48	Severity-Adjusted Probability of Being Cost Effective. <i>Pharmacoeconomics</i> , 2019, 37, 1155-1163.	1.7	50
49	VALUING QALY GAINS BY APPLYING A SOCIETAL PERSPECTIVE. <i>Health Economics (United Kingdom)</i> , 2013, 22, 1272-1281.	0.8	49
50	The Inclusion of Spillover Effects in Economic Evaluations: Not an Optional Extra. <i>Pharmacoeconomics</i> , 2019, 37, 451-456.	1.7	48
51	Measuring Care-Related Quality of Life of Caregivers for Use in Economic Evaluations: CarerQol Tariffs for Australia, Germany, Sweden, UK, and US. <i>Pharmacoeconomics</i> , 2017, 35, 469-478.	1.7	46
52	GET MORE, PAY MORE? An elaborate test of construct validity of willingness to pay per QALY estimates obtained through contingent valuation. <i>Journal of Health Economics</i> , 2012, 31, 158-168.	1.3	45
53	Inquiry into the Relationship between Equity Weights and the Value of the QALY. <i>Value in Health</i> , 2012, 15, 1119-1126.	0.1	43
54	Unpaid work in health economic evaluations. <i>Social Science and Medicine</i> , 2015, 144, 127-137.	1.8	42

#	ARTICLE	IF	CITATIONS
55	Future Costs, Fixed Healthcare Budgets, and the Decision Rules of Cost-Effectiveness Analysis. <i>Health Economics (United Kingdom)</i> , 2016, 25, 237-248.	0.8	41
56	Risk communication during COVID-19: A descriptive study on familiarity with, adherence to and trust in the WHO preventive measures. <i>PLoS ONE</i> , 2021, 16, e0250872.	1.1	41
57	Quality of Life of Nursing Home Residents with Dementia: Validation of the German Version of the ICECAP-O. <i>PLoS ONE</i> , 2014, 9, e92016.	1.1	41
58	Children with an Autism Spectrum Disorder and Their Caregivers: Capturing Health-Related and Care-Related Quality of Life. <i>Journal of Autism and Developmental Disorders</i> , 2020, 50, 263-277.	1.7	40
59	A noticeable difference? Productivity costs related to paid and unpaid work in economic evaluations on expensive drugs. <i>European Journal of Health Economics</i> , 2016, 17, 391-402.	1.4	39
60	A cost-effectiveness threshold based on the marginal returns of cardiovascular hospital spending. <i>Health Economics (United Kingdom)</i> , 2019, 28, 87-100.	0.8	39
61	Time Is Money: Investigating the Value of Leisure Time and Unpaid Work. <i>Value in Health</i> , 2018, 21, 1428-1436.	0.1	38
62	The invisible hands made visible: recognizing the value of informal care in healthcare decision-making. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2008, 8, 557-561.	0.7	37
63	The influence of subjective expectations about length and quality of life on time trade-off answers. <i>Health Economics (United Kingdom)</i> , 2004, 13, 819-823.	0.8	36
64	The New Myth. <i>Pharmacoeconomics</i> , 2008, 26, 1-4.	1.7	34
65	Future Costs in Cost-Effectiveness Analyses: Past, Present, Future. <i>Pharmacoeconomics</i> , 2019, 37, 119-130.	1.7	33
66	Valuing QALYs in Relation to Equity Considerations Using a Discrete Choice Experiment. <i>Pharmacoeconomics</i> , 2015, 33, 1289-1300.	1.7	31
67	The Challenge of Conditional Reimbursement: Stopping Reimbursement Can Be More Difficult Than Not Starting in the First Place!. <i>Value in Health</i> , 2017, 20, 118-125.	0.1	31
68	How to Calculate Indirect Costs in Economic Evaluations. <i>Pharmacoeconomics</i> , 1998, 13, 563-569.	1.7	30
69	The Perseverance Time of Informal Carers of Dementia Patients: Validation of a New Measure to Initiate Transition of Care at Home to Nursing Home Care. <i>Journal of Alzheimer's Disease</i> , 2014, 40, 631-642.	1.2	30
70	A long life in good health: subjective expectations regarding length and future health-related quality of life. <i>European Journal of Health Economics</i> , 2016, 17, 577-589.	1.4	30
71	Blood donation in times of crisis: Early insight into the impact of COVID-19 on blood donors and their motivation to donate across European countries. <i>Vox Sanguinis</i> , 2021, 116, 1031-1041.	0.7	30
72	Lifestyle intervention: from cost savings to value for money. <i>Journal of Public Health</i> , 2010, 32, 440-447.	1.0	28

#	ARTICLE	IF	CITATIONS
73	Equity Weights for Priority Setting in Healthcare: Severity, Age, or Both?. <i>Value in Health</i> , 2019, 22, 1441-1449.	0.1	28
74	The missing link: on the line between C and E. <i>Health Economics (United Kingdom)</i> , 2003, 12, 629-636.	0.8	26
75	Does the EQ-5D Reflect Lost Earnings?. <i>Pharmacoeconomics</i> , 2012, 30, 47-61.	1.7	25
76	Future unrelated medical costs need to be considered in cost effectiveness analysis. <i>European Journal of Health Economics</i> , 2019, 20, 1-5.	1.4	25
77	Subjective expectations regarding length and health-related quality of life in Hungary: results from an empirical investigation. <i>Health Expectations</i> , 2014, 17, 696-709.	1.1	24
78	Are some QALYs more equal than others?. <i>European Journal of Health Economics</i> , 2016, 17, 117-127.	1.4	24
79	QALYs without bias? Nonparametric correction of time trade-off and standard gamble weights based on prospect theory. <i>Health Economics (United Kingdom)</i> , 2019, 28, 843-854.	0.8	24
80	The Value of Correcting Values: Influence and Importance of Correcting TTO Scores for Time Preference. <i>Value in Health</i> , 2010, 13, 879-884.	0.1	23
81	Unrelated Future Costs and Unrelated Future Benefits: Reflections on NICE Guide to the Methods of Technology Appraisal. <i>Health Economics (United Kingdom)</i> , 2016, 25, 933-938.	0.8	23
82	Priority care for employees: A blessing in disguise?. , 1999, 8, 65-73.		22
83	Priority to End of Life Treatments? Views of the Public in the Netherlands. <i>Value in Health</i> , 2017, 20, 107-117.	0.1	22
84	Valid Outcome Measures in Care for Older People: Comparing the ASCOT and the ICECAP-O. <i>Value in Health</i> , 2017, 20, 936-944.	0.1	22
85	The burden of informal caregiving in Hungary, Poland and Slovenia: results from national representative surveys. <i>European Journal of Health Economics</i> , 2019, 20, 5-16.	1.4	22
86	Measuring Health Spillover Effects in Caregivers of Children with Autism Spectrum Disorder: A Comparison of the EQ-5D-3L and SF-6D. <i>Pharmacoeconomics</i> , 2019, 37, 609-620.	1.7	22
87	How do combinations of unhealthy behaviors relate to attitudinal factors and subjective health among the adult population in the Netherlands?. <i>BMC Public Health</i> , 2020, 20, 441.	1.2	22
88	The Mental Health Quality of Life Questionnaire (MHQoL): development and first psychometric evaluation of a new measure to assess quality of life in people with mental health problems. <i>Quality of Life Research</i> , 2022, 31, 633-643.	1.5	22
89	Are all health gains equally important? An exploration of acceptable health as a reference point in health care priority setting. <i>Health and Quality of Life Outcomes</i> , 2015, 13, 79.	1.0	21
90	Rational expectations? An explorative study of subjective survival probabilities and lifestyle across Europe. <i>Health Expectations</i> , 2016, 19, 121-137.	1.1	21

#	ARTICLE	IF	CITATIONS
91	Measurement Instruments of Productivity Loss of Paid and Unpaid Work: A Systematic Review and Assessment of Suitability for Health Economic Evaluations From a Societal Perspective. <i>Value in Health</i> , 2021, 24, 1686-1699.	0.1	21
92	The Monetary Value of Informal Care: Obtaining Pure Time Valuations Using a Discrete Choice Experiment. <i>Pharmacoeconomics</i> , 2019, 37, 531-540.	1.7	20
93	Willingness to pay for an early warning system for infectious diseases. <i>European Journal of Health Economics</i> , 2020, 21, 763-773.	1.4	20
94	Predicting productivity based on EQ-5D: an explorative study. <i>European Journal of Health Economics</i> , 2014, 15, 465-475.	1.4	19
95	From representing views to representativeness of views: Illustrating a new (Q2S) approach in the context of health care priority setting in nine European countries. <i>Social Science and Medicine</i> , 2016, 166, 205-213.	1.8	19
96	Views of older people in the Netherlands on wellbeing: A Q-methodology study. <i>Social Science and Medicine</i> , 2019, 240, 112535.	1.8	19
97	Can we fix it? Yes we can! But what? A new test of procedural invariance in TTO measurement. <i>Health Economics (United Kingdom)</i> , 2008, 17, 877-885.	0.8	18
98	The impact of informal care for patients with Pompe disease: An application of the CarerQol instrument. <i>Molecular Genetics and Metabolism</i> , 2013, 110, 281-286.	0.5	18
99	Married with children—the influence of significant others in TTO exercises. <i>Health and Quality of Life Outcomes</i> , 2015, 13, 94.	1.0	18
100	Willingness to Pay for Health-Related Quality of Life Gains in Relation to Disease Severity and the Age of Patients. <i>Value in Health</i> , 2021, 24, 1182-1192.	0.1	18
101	Discounting in decision making: the consistency argument revisited empirically. <i>Health Policy</i> , 2004, 67, 187-194.	1.4	16
102	The efficiency frontier approach to economic evaluation: will it help German policy making?. <i>Health Economics (United Kingdom)</i> , 2010, 19, 1128-1131.	0.8	16
103	Economics and public health: engaged to be happily married!. <i>European Journal of Public Health</i> , 2007, 17, 122-123.	0.1	15
104	Lifecycle evidence requirements for high-risk implantable medical devices: a European perspective. <i>Expert Review of Medical Devices</i> , 2020, 17, 993-1006.	1.4	15
105	Challenges with coverage with evidence development schemes for medical devices: A systematic review. <i>Health Policy and Technology</i> , 2020, 9, 146-156.	1.3	15
106	Breaking the Silence: Exploring the Potential Effects of Explicit Instructions on Incorporating Income and Leisure in TTO Exercises. <i>Value in Health</i> , 2009, 12, 172-180.	0.1	14
107	Does living longer in good health facilitate longer working lives? The relationship between disability and working lives. <i>European Journal of Public Health</i> , 2015, 25, 791-795.	0.1	14
108	Who should receive treatment? An empirical enquiry into the relationship between societal views and preferences concerning healthcare priority setting. <i>PLoS ONE</i> , 2018, 13, e0198761.	1.1	14

#	ARTICLE	IF	CITATIONS
109	Does the ICECAP-O cover the physical, mental and social functioning of older people in the UK? Quality of Life Research, 2019, 28, 761-770.	1.5	14
110	Well-being of Older People (WOOP): Quantitative validation of a new outcome measure for use in economic evaluations. Social Science and Medicine, 2020, 259, 113109.	1.8	14
111	The Healthy Aging Index analyzed over 15 years in the general population: The Doetinchem Cohort Study. Preventive Medicine, 2020, 139, 106193.	1.6	13
112	What is it going to be, TTO or SG? A direct test of the validity of health state valuation. Health Economics (United Kingdom), 2020, 29, 1475-1481.	0.8	13
113	Coverage with evidence development schemes for medical devices in Europe: characteristics and challenges. European Journal of Health Economics, 2021, 22, 1253-1273.	1.4	13
114	Productivity of Working at Home and Time Allocation Between Paid Work, Unpaid Work and Leisure Activities During a Pandemic. Pharmacoeconomics, 2022, 40, 77-90.	1.7	13
115	The Incorporation of Income and Leisure in Health State Valuations When the Measure Is Silent: An Empirical Inquiry into the Sound of Silence. Medical Decision Making, 2009, 29, 503-512.	1.2	12
116	Pharmacoeconomic Guidelines Should Prescribe Inclusion of Indirect Medical Costs! A Response to Grima et al.. Pharmacoeconomics, 2013, 31, 369-373.	1.7	12
117	The perseverance time of informal carers for people with dementia: results of a two-year longitudinal follow-up study. BMC Nursing, 2015, 14, 56.	0.9	12
118	The Impact of Hospital Payment Schemes on Healthcare and Mortality: Evidence from Hospital Payment Reforms in OECD Countries. Health Economics (United Kingdom), 2016, 25, 1005-1019.	0.8	12
119	Exploring a new method for deriving the monetary value of a QALY. European Journal of Health Economics, 2016, 17, 801-809.	1.4	12
120	What should we know about the person behind a TTO?. European Journal of Health Economics, 2018, 19, 1207-1211.	1.4	12
121	The Corrective Approach: Policy Implications of Recent Developments in QALY Measurement Based on Prospect Theory. Value in Health, 2019, 22, 816-821.	0.1	12
122	Living up to expectations: Experimental tests of subjective life expectancy as reference point in time trade-off and standard gamble. Journal of Health Economics, 2020, 71, 102318.	1.3	12
123	Altruistic Preferences in Time Tradeoff. Medical Decision Making, 2016, 36, 187-198.	1.2	11
124	How to value safety in economic evaluations in health care? A review of applications in different sectors. European Journal of Health Economics, 2019, 20, 1041-1061.	1.4	11
125	How does participating in a deliberative citizens panel on healthcare priority setting influence the views of participants?. Health Policy, 2020, 124, 143-151.	1.4	11
126	Costs and benefits of early response in the Ebola virus disease outbreak in Sierra Leone. Cost Effectiveness and Resource Allocation, 2020, 18, 13.	0.6	11

#	ARTICLE	IF	CITATIONS
127	A validation study of the CarerQol instrument in informal caregivers of people with dementia from eight European countries. <i>Quality of Life Research</i> , 2021, 30, 577-588.	1.5	11
128	What works better for preference elicitation among older people? Cognitive burden of discrete choice experiment and case 2 best-worst scaling in an online setting. <i>Journal of Choice Modelling</i> , 2021, 38, 100265.	1.2	11
129	Content validation of the Well-being of Older People measure (WOOP). <i>Health and Quality of Life Outcomes</i> , 2021, 19, 200.	1.0	11
130	Instruments to assess quality of life in people with mental health problems: a systematic review and dimension analysis of generic, domain- and disease-specific instruments. <i>Health and Quality of Life Outcomes</i> , 2021, 19, 249.	1.0	11
131	A QALY loss is a QALY loss is a QALY loss: a note on independence of loss aversion from health states. <i>European Journal of Health Economics</i> , 2019, 20, 419-426.	1.4	10
132	Estimating the monetary value of health and capability well-being applying the well-being valuation approach. <i>European Journal of Health Economics</i> , 2020, 21, 1235-1244.	1.4	10
133	Broadening the application of health technology assessment in the Netherlands: a worthwhile destination but not an easy ride?. <i>Health Economics, Policy and Law</i> , 2021, 16, 440-456.	1.1	10
134	The relative value of carer and patient quality of life: A person trade-off (PTO) study. <i>Social Science and Medicine</i> , 2022, 292, 114556.	1.8	10
135	“Back to the future” Influence of beliefs regarding the future on TTO answers. <i>Health and Quality of Life Outcomes</i> , 2016, 14, 4.	1.0	9
136	Acceptable health and priority weighting: Discussing a reference-level approach using sufficientarian reasoning. <i>Social Science and Medicine</i> , 2017, 181, 158-167.	1.8	9
137	New findings from the time trade-off for income approach to elicit willingness to pay for a quality adjusted life year. <i>European Journal of Health Economics</i> , 2018, 19, 277-291.	1.4	9
138	Some pain, no gain: experiences with the no-claim rebate in the Dutch health care system. <i>Health Economics, Policy and Law</i> , 2009, 4, 405-424.	1.1	8
139	Are people living with HIV less productive at work?. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2018, 30, 1265-1272.	0.6	8
140	A validation study of the ICECAP-O in informal carers of people with dementia from eight European Countries. <i>Quality of Life Research</i> , 2020, 29, 237-251.	1.5	8
141	Did the health of the Dutch population improve between 2001 and 2008? Investigating age- and gender-specific trends in quality of life. <i>European Journal of Health Economics</i> , 2015, 16, 801-811.	1.4	7
142	Estimating an anchored utility tariff for the well-being of older people measure (WOOP) for the Netherlands. <i>Social Science and Medicine</i> , 2022, 301, 114901.	1.8	7
143	A short note on measuring subjective life expectancy: survival probabilities versus point estimates. <i>European Journal of Health Economics</i> , 2017, 18, 7-12.	1.4	6
144	Indicators to facilitate the early identification of patients with major depressive disorder in need of highly specialized care: A concept mapping study. <i>Depression and Anxiety</i> , 2018, 35, 346-352.	2.0	6

#	ARTICLE	IF	CITATIONS
145	Integrating clinical and economic evidence in clinical guidelines: More needed than ever!. <i>Journal of Evaluation in Clinical Practice</i> , 2019, 25, 561-564.	0.9	6
146	Development of Population Tariffs for the CarerQol Instrument for Hungary, Poland and Slovenia: A Discrete Choice Experiment Study to Measure the Burden of Informal Caregiving. <i>Pharmacoeconomics</i> , 2020, 38, 633-643.	1.7	6
147	Validation of the Hungarian version of the CarerQol instrument in informal caregivers: results from a cross-sectional survey among the general population in Hungary. <i>Quality of Life Research</i> , 2021, 30, 629-641.	1.5	6
148	Coverage with evidence development for medical devices in Europe: Can practice meet theory?. <i>Health Economics (United Kingdom)</i> , 2022, 31, 179-194.	0.8	6
149	In Absence of Absenteeism: Some Thoughts on Productivity Costs in Economic Evaluations in a Post-corona Era. <i>Pharmacoeconomics</i> , 2022, 40, 7-11.	1.7	6
150	Psychometric evaluation of the Health-Risk Attitude Scale (HRAS-13): assessing the reliability, dimensionality and validity in the general population and a patient population. <i>Psychology and Health</i> , 2022, 37, 34-50.	1.2	5
151	Happy with Your Capabilities? Valuing ICECAP-O and ICECAP-A States Based on Experienced Utility Using Subjective Well-Being Data. <i>Medical Decision Making</i> , 2020, 40, 498-510.	1.2	5
152	Willingness to pay for quality and length of life gains in end of life patients of different ages. <i>Social Science and Medicine</i> , 2021, 279, 113987.	1.8	5
153	Estimating an exchange rate between care-related and health-related quality of life outcomes for economic evaluation: An application of the wellbeing valuation method. <i>Health Economics (United Kingdom)</i> , 2021, 30, 2847-2857.	0.8	5
154	Life satisfaction: The role of domain-specific reference points. <i>Health Economics (United Kingdom)</i> , 2021, 30, 2766-2779.	0.8	5
155	Caring for Children with an Autism Spectrum Disorder: Factors Associating with Health- and Care-Related Quality of Life of the Caregivers. <i>Journal of Autism and Developmental Disorders</i> , 2022, 52, 4665-4678.	1.7	5
156	Implementation of coverage with evidence development schemes for medical devices: A decision tool for late technology adopter countries. <i>Health Economics (United Kingdom)</i> , 2022, , .	0.8	5
157	The decision tool unipolar depression (DTUD): a new measure to facilitate the early identification of patients with major depressive disorder in need of highly specialized care. <i>BMC Psychiatry</i> , 2019, 19, 179.	1.1	4
158	Don't forget about the future: The impact of including future costs on the cost-effectiveness of adult pneumococcal conjugate vaccination with PCV13 in the Netherlands. <i>Vaccine</i> , 2021, 39, 3834-3843.	1.7	4
159	Did the COVID-19 pandemic change the willingness to pay for an early warning system for infectious diseases in Europe?. <i>European Journal of Health Economics</i> , 2022, 23, 81-94.	1.4	4
160	Productivity Costs Measurement Through Quality of Life? A Response to the Recommendation of the Washington Panel. , 1997, 6, 253.		4
161	Challenges in economic evaluations in obstetric care: a scoping review and expert opinion. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2020, 127, 1399-1407.	1.1	4
162	Primary care in cancer control: towards mature cancer care. <i>Lancet Oncology</i> , The, 2015, 16, 1226-1227.	5.1	3

#	ARTICLE	IF	CITATIONS
163	Acceptable health and ageing: results of a cross-sectional study from Hungary. <i>Health and Quality of Life Outcomes</i> , 2020, 18, 346.	1.0	3
164	Costs and benefits of interventions aimed at major infectious disease threats: lessons from the literature. <i>European Journal of Health Economics</i> , 2020, 21, 1329-1350.	1.4	3
165	Distributional consequences of including survivor costs in economic evaluations. <i>Health Economics (United Kingdom)</i> , 2021, 30, 2606-2613.	0.8	3
166	Do Profit Margins of Pharmaceuticals Influence Reimbursement Decisions? A Discrete Choice Experiment Among Dutch Healthcare Decision Makers. <i>Value in Health</i> , 2022, 25, 222-229.	0.1	3
167	Good Days and Bad Days: Measuring Health-Related Quality of Life in People With Epilepsy. <i>Value in Health</i> , 2021, 24, 1470-1475.	0.1	3
168	Estimating the costs of non-medical consumption in life-years gained for economic evaluations. <i>Social Science and Medicine</i> , 2021, 289, 114414.	1.8	3
169	Mixed evidence for the compression of morbidity hypothesis for smoking elimination—a systematic literature review. <i>European Journal of Public Health</i> , 2021, 31, 409-417.	0.1	3
170	The evaluation of lifestyle interventions in the Netherlands. <i>Health Economics, Policy and Law</i> , 2012, 7, 243-261.	1.1	2
171	Peer effects in health valuation: the relation between rating of contemporaries' health and own health. <i>Health and Quality of Life Outcomes</i> , 2018, 16, 148.	1.0	2
172	Performance-based risk-sharing agreements in renal care: current experience and future prospects. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2021, 21, 197-210.	0.7	2
173	Trust me; I know what I am doing investigating the effect of choice list elicitation and domain-relevant training on preference reversals in decision making for others. <i>European Journal of Health Economics</i> , 2021, 22, 679-697.	1.4	2
174	The value of health—Empirical issues when estimating the monetary value of a quality-adjusted life year based on well-being data. <i>Health Economics (United Kingdom)</i> , 2021, 30, 1849-1870.	0.8	2
175	I costi sanitari indiretti (non correlati) durante gli anni di vita guadagnati. <i>Pharmacoeconomics Italian Research Articles</i> , 2009, 11, 55-70.	0.2	1
176	Una panoramica delle metodologie per la valutazione delle cure informali negli studi di economia sanitaria. <i>Pharmacoeconomics Italian Research Articles</i> , 2008, 10, 99-111.	0.2	0
177	Development and psychometric evaluation of the Transdiagnostic Decision Tool: matched care for patients with a mental disorder in need of highly specialised care. <i>BJPsych Open</i> , 2020, 6, .	0.3	0
178	Development and psychometric evaluation of the Decision Tool Anxiety Disorders, OCD and PTSD (DTAOP): Facilitating the early detection of patients in need of highly specialized care. <i>PLoS ONE</i> , 2021, 16, e0256384.	1.1	0
179	Title is missing!. , 2020, 15, e0238858.		0
180	Title is missing!. , 2020, 15, e0238858.		0

#	ARTICLE	IF	CITATIONS
181	Title is missing!. , 2020, 15, e0238858.		0
182	Title is missing!. , 2020, 15, e0238858.		0